MX2023001481A - Metodos para tratar pacientes con hipercolesterolemia refractaria. - Google Patents
Metodos para tratar pacientes con hipercolesterolemia refractaria.Info
- Publication number
- MX2023001481A MX2023001481A MX2023001481A MX2023001481A MX2023001481A MX 2023001481 A MX2023001481 A MX 2023001481A MX 2023001481 A MX2023001481 A MX 2023001481A MX 2023001481 A MX2023001481 A MX 2023001481A MX 2023001481 A MX2023001481 A MX 2023001481A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hypercholesterolemia
- involving
- statin
- treating refractory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062990P | 2020-08-07 | 2020-08-07 | |
| US202163135946P | 2021-01-11 | 2021-01-11 | |
| PCT/US2021/045008 WO2022032137A1 (en) | 2020-08-07 | 2021-08-06 | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001481A true MX2023001481A (es) | 2023-03-08 |
Family
ID=77543654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001481A MX2023001481A (es) | 2020-08-07 | 2021-08-06 | Metodos para tratar pacientes con hipercolesterolemia refractaria. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220072127A1 (https=) |
| EP (1) | EP4192446A1 (https=) |
| JP (1) | JP2023538522A (https=) |
| KR (1) | KR20230050379A (https=) |
| CN (1) | CN116096365A (https=) |
| AU (1) | AU2021320417A1 (https=) |
| BR (1) | BR112023002085A2 (https=) |
| CA (1) | CA3188213A1 (https=) |
| IL (1) | IL300429A (https=) |
| MX (1) | MX2023001481A (https=) |
| WO (1) | WO2022032137A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| KR20240167914A (ko) * | 2022-04-04 | 2024-11-28 | 이노자임 파마, 인코포레이티드 | Enpp1 결핍증 및 abcc6 결핍증의 치료 |
| WO2025185644A1 (zh) * | 2024-03-05 | 2025-09-12 | 江苏恒瑞医药股份有限公司 | 抗angptl3抗体治疗高血脂症的用途及方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| RU2723018C2 (ru) * | 2014-07-16 | 2020-06-08 | Санофи Байотекнолоджи | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию |
| PL3169353T3 (pl) * | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
| JP7541810B2 (ja) * | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| KR20180132843A (ko) * | 2016-04-08 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법 |
| IL293308B2 (en) * | 2016-04-28 | 2024-12-01 | Regeneron Pharma | Methods for treating patients with familial hypercholesterolemia |
-
2021
- 2021-08-06 AU AU2021320417A patent/AU2021320417A1/en not_active Abandoned
- 2021-08-06 CA CA3188213A patent/CA3188213A1/en active Pending
- 2021-08-06 MX MX2023001481A patent/MX2023001481A/es unknown
- 2021-08-06 JP JP2023507911A patent/JP2023538522A/ja not_active Abandoned
- 2021-08-06 IL IL300429A patent/IL300429A/en unknown
- 2021-08-06 US US17/396,399 patent/US20220072127A1/en not_active Abandoned
- 2021-08-06 WO PCT/US2021/045008 patent/WO2022032137A1/en not_active Ceased
- 2021-08-06 EP EP21762903.9A patent/EP4192446A1/en not_active Withdrawn
- 2021-08-06 BR BR112023002085A patent/BR112023002085A2/pt unknown
- 2021-08-06 KR KR1020237007956A patent/KR20230050379A/ko active Pending
- 2021-08-06 CN CN202180058786.0A patent/CN116096365A/zh not_active Withdrawn
-
2023
- 2023-12-12 US US18/537,578 patent/US20240197870A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20240197870A1 (en) | 2024-06-20 |
| WO2022032137A1 (en) | 2022-02-10 |
| JP2023538522A (ja) | 2023-09-08 |
| BR112023002085A2 (pt) | 2023-02-28 |
| AU2021320417A1 (en) | 2023-03-30 |
| KR20230050379A (ko) | 2023-04-14 |
| CN116096365A (zh) | 2023-05-09 |
| EP4192446A1 (en) | 2023-06-14 |
| IL300429A (en) | 2023-04-01 |
| US20220072127A1 (en) | 2022-03-10 |
| CA3188213A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001481A (es) | Metodos para tratar pacientes con hipercolesterolemia refractaria. | |
| AU2017258105A1 (en) | Methods for treating patients with familial hypercholesterolemia | |
| PH12021552675A1 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
| MX386832B (es) | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. | |
| MX2022013163A (es) | Anticuerpo contra nectin-4 y aplicacion del mismo. | |
| TW200505481A (en) | Compositions and methods for treating coagulation related disorders | |
| BRPI0211953B8 (pt) | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro | |
| MX2023002805A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos. | |
| NZ592786A (en) | Methods and compositions for treating complement-associated disorders using eculizumab | |
| WO2019160751A3 (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| MX2023011507A (es) | Conjugado anticuerpo- farmaco que incluye un anticuerpo contra la cldn18.2 humana y uso del mismo. | |
| WO2021259927A3 (en) | Anti-cd2 antibodies | |
| MX2025008092A (es) | Inhibidores de kif18a y usos de los mismos | |
| MX2023014069A (es) | Composiciones y métodos para el tratamiento del cáncer de próstata. | |
| JOP20220322A1 (ar) | مثبطات pcsk9 وطرق استخدامها لعلاج الاضطرابات المرتبطة بالكوليسترول | |
| MX2022010258A (es) | Composiciones y métodos para tratar la lesión renal. | |
| MX2024007596A (es) | Compuestos dirigidos a egfr-cmet y usos de estos. | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
| MX2023002850A (es) | Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap). | |
| CA3242378A1 (en) | Anti-musk antibodies for use in treating neuromuscular disorders | |
| MX2023003723A (es) | Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico. | |
| CR20230473A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1. | |
| PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
| EA201892444A1 (ru) | Способы лечения пациентов с семейной гиперхолестеринемией | |
| BR112022010934A2 (pt) | Métodos para tratar copd administrando um antagonista de il-33 |